Opioid peptide-derived analgesics
- PMID: 16353933
- PMCID: PMC2751258
- DOI: 10.1208/aapsj070356
Opioid peptide-derived analgesics
Abstract
Two recent developments of opioid peptide-based analgesics are reviewed. The first part of the review discusses the dermorphin-derived, cationic-aromatic tetrapeptide H-Dmt-D-Arg-Phe-Lys-NH(2) ([Dmt(1)]DALDA, where Dmt indicates 2',6'-dimethyltyrosine), which showed subnanomolar mu receptor binding affinity, extraordinary mu receptor selectivity, and high mu agonist potency in vitro. In vivo, [Dmt(1)]DALDA looked promising as a spinal analgesic because of its extraordinary antinociceptive effect (3000 times more potent than morphine) in the mouse tail-flick assay, long duration of action (4 times longer than morphine), and lack of effect on respiration. Unexpectedly, [Dmt(1)]DALDA also turned out to be a potent and long-acting analgesic in the tail-flick test when given subcutaneously (s.c.), indicating that it is capable of crossing the blood-brain barrier. Furthermore, little or no cross-tolerance was observed with s.c. [Dmt(1)]DALDA in morphine-tolerant mice. The second part of the review concerns the development of mixed mu agonist/delta antagonists that, on the basis of much evidence, are expected to be analgesics with a low propensity to produce tolerance and physical dependence. The prototype pseudopeptide H-Dmt-TicPsi[CH(2)NH]Phe-Phe-NH(2) (DIPP-NH(2)[Psi], where Tic indicates 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid) showed subnanomolar mu and delta receptor binding affinities and the desired mu agonist/delta antagonist profile in vitro. DIPP-NH(2)[Psi] produced a potent analgesic effect after intracerebroventricular administration in the rat tail-flick assay, no physical dependence, and less tolerance than morphine. The results obtained with DIPP-NH(2)[Psi] indicate that mixed mu agonist/delta antagonists look promising as analgesic drug candidates, but compounds with this profile that are systemically active still need to be developed.
Similar articles
-
The opioid mu agonist/delta antagonist DIPP-NH(2)[Psi] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats.J Med Chem. 1999 Sep 9;42(18):3520-6. doi: 10.1021/jm980724+. J Med Chem. 1999. PMID: 10479285
-
Profound spinal tolerance after repeated exposure to a highly selective mu-opioid peptide agonist: role of delta-opioid receptors.J Pharmacol Exp Ther. 2002 Jul;302(1):188-96. doi: 10.1124/jpet.302.1.188. J Pharmacol Exp Ther. 2002. PMID: 12065716
-
The TIPP opioid peptide family: development of delta antagonists, delta agonists, and mixed mu agonist/delta antagonists.Biopolymers. 1999;51(6):411-25. doi: 10.1002/(SICI)1097-0282(1999)51:6<411::AID-BIP4>3.0.CO;2-Z. Biopolymers. 1999. PMID: 10797230 Review.
-
[Dmt(1)]DALDA is highly selective and potent at mu opioid receptors, but is not cross-tolerant with systemic morphine.Curr Med Chem. 2002 Jan;9(1):31-9. doi: 10.2174/0929867023371445. Curr Med Chem. 2002. PMID: 11860345
-
Dermorphin tetrapeptide analogs as potent and long-lasting analgesics with pharmacological profiles distinct from morphine.Peptides. 2011 Feb;32(2):421-7. doi: 10.1016/j.peptides.2010.11.013. Epub 2010 Nov 30. Peptides. 2011. PMID: 21126548 Review.
Cited by
-
Identification and Pharmacological Characterization of a Low-Liability Antinociceptive Bifunctional MOR/DOR Cyclic Peptide.Molecules. 2023 Nov 11;28(22):7548. doi: 10.3390/molecules28227548. Molecules. 2023. PMID: 38005269 Free PMC article.
-
Bis-Cyclic Guanidine Heterocyclic Peptidomimetics as Opioid Ligands with Mixed μ-, κ- and δ-Opioid Receptor Interactions: A Potential Approach to Novel Analgesics.Int J Mol Sci. 2022 Aug 25;23(17):9623. doi: 10.3390/ijms23179623. Int J Mol Sci. 2022. PMID: 36077029 Free PMC article.
-
Elucidating the active δ-opioid receptor crystal structure with peptide and small-molecule agonists.Sci Adv. 2019 Nov 27;5(11):eaax9115. doi: 10.1126/sciadv.aax9115. eCollection 2019 Nov. Sci Adv. 2019. PMID: 31807708 Free PMC article.
-
The multifunctional peptide DN-9 produced peripherally acting antinociception in inflammatory and neuropathic pain via μ- and κ-opioid receptors.Br J Pharmacol. 2020 Jan;177(1):93-109. doi: 10.1111/bph.14848. Epub 2019 Dec 23. Br J Pharmacol. 2020. PMID: 31444977 Free PMC article.
-
Characterization of cyclic peptides containing disulfide bonds.J Pharm Biomed Anal. 2015 May 10;109:112-20. doi: 10.1016/j.jpba.2015.01.009. Epub 2015 Jan 22. J Pharm Biomed Anal. 2015. PMID: 25778927 Free PMC article.
References
-
- Yaksh TL. In vivo studies on spinal opiate receptor systems mediating antinociception, I: mu and delta receptor profiles in the primate. J Pharmacol Exp Ther. 1983;226:303–316. - PubMed
-
- Porreca F, Mosberg HI, Hurst R, Hruby VJ, Burks TF. Roles of mu, delta and kappa opioid receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse. J Pharmacol Exp Ther. 1984;230:341–348. - PubMed
-
- Cowan A, Zhu XZ, Mosberg HI, Omnaas JR, Porreca F. Direct dependence studies in rats with agents selective for different types of opioid receptor. J Pharmacol Exp Ther. 1988;246:950–955. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials